Toshiro Ogura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3693906/publications.pdf

Version: 2024-02-01

1040056 940533 16 399 9 16 citations h-index g-index papers 16 16 16 867 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | An International Retrospective Observational Study of Liver Functional Deterioration after Repeat Liver Resection for Patients with Hepatocellular Carcinoma. Cancers, 2022, 14, 2598. | 3.7 | 4 |
| 2 | C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Scientific Reports, 2021, 11, 10078. | 3.3 | 14 |
| 3 | Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels. Cancers, 2021, 13, 3187. | 3.7 | 10 |
| 4 | Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. PLoS ONE, 2021, 16, e0252917. | 2.5 | 12 |
| 5 | Downregulated Pancreatic Beta Cell Genes Indicate Poor Prognosis in Patients With Pancreatic Neuroendocrine Neoplasms. Annals of Surgery, 2020, 271, 732-739. | 4.2 | 10 |
| 6 | Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 114-123. | 2.6 | 3 |
| 7 | Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma. Carcinogenesis, 2020, 41, 734-742. | 2.8 | 24 |
| 8 | Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms. Journal of Cancer Research and Clinical Oncology, 2020, 146, 793-799. | 2.5 | 9 |
| 9 | Position of the Pancreas Division Line and Postoperative Outcomes After Distal Pancreatectomy. World Journal of Surgery, 2020, 44, 1244-1251. | 1.6 | 2 |
| 10 | Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2097-2104. | 2.5 | 3 |
| 11 | The Clinical Implications of Peripancreatic Fluid Collection After Distal Pancreatectomy. World Journal of Surgery, 2019, 43, 2069-2076. | 1.6 | 16 |
| 12 | A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. Journal of Gastroenterology, 2019, 54, 819-828. | 5.1 | 8 |
| 13 | Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. International Journal of Cancer, 2019, 145, 192-205. | 5.1 | 48 |
| 14 | Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine, 2019, 40, 457-470. | 6.1 | 177 |
| 15 | Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1155-1163. | 2.5 | 33 |
| 16 | The <i>RAS</i> mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of allâ€ <i>RAS</i> . Journal of Surgical Oncology, 2018, 117, 745-755. | 1.7 | 26 |